Crysforma’s activity

Crysforma provides complete scientific support for the discovery, analysis and scale-up of polymorphs, hydrates, amorphous phases, salts and co-crystals of active pharmaceutical ingredients or intermediates.

Crysforma has developed its own crystallization screening methodology based on the combination of several crystallization procedures. We use high-throughput crystallization systems controlled by highly skilled scientists to maximize the information drawn from each experiment (read more).


Highlights 2017

  • Crysforma has worked for many years to reach international industrial partners. During 2017, nearly 45% of the income generated by Crysforma came from international collaborations. Crysforma collaborated with companies from Germany, China, the Netherlands or Ireland, among others.

CSOL’s activity:

CSOL’s mission is to act as the link between the researchers’ expertise and the industry, as well as developing the researchers’ discoveries into industrial applications with a comprehensive approach. (read more)

Highlights 2017

During 2017 CSOL has been working on nine valorization projects aimed at further developing inventions or know-how of ICIQ groups:

  • New modular organocatalysts (Prof. PericĂ s): Family of organocatalysts and activity screening
  • Supported chiral phosphoric acids (Prof. PericĂ s): Development of a reproducible and scalable route
  • Preparation of Englerin A analogs (Prof. Echavarren, in collaboration with NCI (USA))
  • CO2hydrogenation at high pressure for methanol production (Prof. Urakawa, project funded by Obra Social La Caixa).
  • New MOFs for the separation of CO2in gas mixtures (Prof. GalĂĄn-MascarĂłs, project funded by Obra Social La Caixa).
  • Preparation of stable gold and silver catalysts and pre-catalysts (Prof. Echavarren, project funded by Obra Social La Caixa).
  • Development of diagnostic platform through biomolecule detection by quantum dot fluorescence (Prof. Palomares, project funded by Obra Social La Caixa).
  • Monomer preparation (CIEN-SURCAR project with Leitat technology center and the industrial company Cromogenia)
  • Industrial project for the preparation of new compounds with fungicide activity for Syngenta (Prof. Shafir)

ERTFLOW works in the areas of flow chemistry and anchoring of homogeneous catalysts.

Ertflow provides R&D services to the pharmaceutical and fine chemical industry. In 2017 the main areas of activity were the transformation of batch processes into flow processes, and the continuous synthesis of medicinal chemistry libraries.

The collaboration with the pharmaceutical group Esteve within the MINECO Retos ColaboraciĂłn project FLOW4HEALTH, continued during 2017.

During 2017, in collaboration with the German biotech company Aicuris, Ertflow was granted an European Industrial Doctorate project (Viro-Flow) involving 3 PhD students. The students will join ICIQ and Aicuris during the spring of 2018. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie SkƂodowska-Curie grant agreement No 766058.

In parallel to these and other industrial collaborations, Ertflow collaborated with several research centers to develop new technologies and products of industrial interest.